Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Interventions: Paclitaxel, CB-839; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Birmingham, Alabama • Mobile, Alabama • New Haven, Connecticut + 20 more

Conditions: Atopic Dermatitis
Interventions: Abrocitinib; Drug
Lead sponsor: Innovaderm Research Inc.; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Fountain Valley, California • Miami Lakes, Florida + 3 more

Conditions: Acute Bacterial Infections, Acute Viral Infections
Interventions: Not listed
Lead sponsor: The Plasma Source; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Southampton, Pennsylvania

Conditions: Infections, Herpesviridae
Interventions: Valaciclovir, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Carmichael, California • Davis, California • Riverside, California + 13 more

Conditions: Vascular Ehlers-Danlos Syndrome
Interventions: Heartmath Intervention, Control Group; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: LEO 138559, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Fountain Valley, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Melanoma (Skin)
Interventions: oblimersen sodium, dacarbazine; Biological · Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Los Angeles, California • Berkeley Heights, New Jersey

Conditions: Breast Cancer
Interventions: trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acne Vulgaris
Interventions: Low Strength IDP-107, High Strength IDP-107, Placebo Comparator; Drug
Lead sponsor: Dow Pharmaceutical Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 25
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 22 more

Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions: Not listed
Lead sponsor: Viatar LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lawrence, Massachusetts

Conditions: Melasma
Interventions: Lytera 2.0, 4% Hydroquinone Topical Cream, SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen; Other · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Herpes Labialis, Herpes Simplex Virus
Interventions: Glutamine, Glycine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acne Vulgaris
Interventions: Dapsone plus Adapalene, Clindamycin/benzoyl peroxide plus Adapalene; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
Interventions: sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis, hypertonic saline; Biological · Procedure · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Research Blood Collection; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Pre-test Assessment, Pre test Counseling, Blood draw, Post-test counseling, and post-test assessment, Follow-up assessments (6 and 12 months); Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Hidradenitis Suppurativa
Interventions: INCB054707; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • New York, New York + 1 more

Conditions: Erythropoietic Protoporphyria
Interventions: Afamelanotide, Placebo; Drug
Lead sponsor: Clinuvel Pharmaceuticals Limited; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 3 more

Conditions: HIV Infections, HIV Wasting Syndrome, Lipodystrophy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 12 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 2
States / cities: The Bronx, New York • Houston, Texas

Conditions: Eczema
Interventions: Topical B12 0.07%; Drug
Lead sponsor: Spartanburg Regional Healthcare System; Other
Eligibility: 6 Months to 18 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Breast Cancer
Interventions: Polyphenon E; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 2
States / cities: Shreveport, Louisiana • New York, New York

Conditions: Metastatic Melanoma
Interventions: CD24Fc, Ipilimumab, Nivolumab; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: ISIS 3521, ISIS 5132; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 2 more

Conditions: Breast Cancer
Interventions: Bevacizumab, Standard adjuvant chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 44
States / cities: Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more

Search by objective public record fields.

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

300 Antibody Diagnostic Test Kit

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

Collection of Blood Specimens for Circulating Tumor Cell Analysis

Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)

The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children

Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis

A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer